ADC Drug Targets: Research Reagents for Antibody-Drug Conjugate Development

Antibody-drug conjugates (ADCs) combine the targeting specificity of monoclonal antibodies with the cell-killing potency of cytotoxic payloads. With over 10 ADCs now approved globally and 100+ in clinical development, ADCs represent one of the fastest-growing modalities in oncology drug development. The success of an ADC program depends critically on target selection — the target antigen must be highly expressed on tumor cells, minimally expressed on normal tissue, and efficiently internalized upon antibody binding.

This guide covers the key ADC targets driving current clinical programs and the research reagents needed to study them. For a broader overview of all oncology research areas, see our Cancer Research Reagents hub.

Key ADC Targets and Approved Drugs

Research Applications for ADC Target Reagents

Target expression profiling by IHC. Evaluate target antigen expression levels and distribution in tumor tissue using anti-target antibodies on FFPE sections. Expression level often correlates with ADC efficacy. For protocol and troubleshooting guidance, see our IHC Protocol and IHC Panel Design guides.

Internalization assays. Use fluorophore-conjugated anti-target antibodies to measure receptor internalization kinetics by flow cytometry or confocal microscopy — a critical parameter for ADC payload delivery.

Binding kinetics (SPR/BLI). Use recombinant target proteins (ECD domains) as ligands on SPR chips or BLI biosensors to measure antibody-antigen binding affinity and kinetics for ADC candidate screening.

Cell-based potency assays. Recombinant target-expressing stable cell lines and recombinant proteins enable ADCC, CDC, and ADC-mediated cytotoxicity assays for lead candidate selection.

PK/ADA bioanalysis. Research biosimilar versions of approved ADC antibodies (e.g., trastuzumab, sacituzumab) serve as reference standards in pharmacokinetic and immunogenicity assays.

ADC targets are increasingly studied in combination with PD-1/PD-L1 checkpoint inhibitors in clinical trials, requiring multiplex reagents that span both target classes.

Frequently Asked Questions

Q: What is the difference between the naked antibody and the ADC in terms of research reagents?

The research reagents (antibodies and proteins) sold by abinScience are the naked antibody and target protein components — not the drug-conjugated ADC molecule itself. These reagents are used to study the target biology (expression, internalization, binding), develop bioanalytical assays (PK/ADA), and create the binding/functional data needed to support ADC drug development.

Q: Can I use biosimilar trastuzumab for ADC payload conjugation research?

Research biosimilar trastuzumab is suitable for conjugation studies at the research level (non-GMP). It shares the same amino acid sequence and antigen-binding specificity as clinical trastuzumab, making it an appropriate substrate for testing novel linker-payload chemistries, conjugation site strategies, and drug-antibody ratio (DAR) optimization. As a recombinant antibody, it provides batch-to-batch consistency critical for reproducible conjugation experiments.

References

1. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. doi: 10.1038/nrd.2016.268

2. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. doi: 10.1038/s41392-022-00947-7

3. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. doi: 10.1038/s41571-021-00470-8

All products are for research use only. For technical support, contact order@abinscience.com.